Extended-release ketamine tablets offer new hope for treatment-resistant depression

  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 60 sec. here
  • 9 min. at publisher
  • 📊 Quality Score:
  • News: 51%
  • Publisher: 71%

Depression News

Ketamine,Antidepressant,Efficacy

The BEDROC trial found that extended-release ketamine tablets (R-107) significantly improve depressive symptoms in treatment-resistant depression patients, with the 180 mg dose showing the most efficacy. The treatment was well-tolerated with minimal side effects.

By Vijay Kumar MalesuReviewed by Susha Cheriyedath, M.Sc.Jun 26 2024 In a recent study published in the journal Nature Medicine , an international team of researchers evaluated the efficacy, safety, and tolerability of extended-release ketamine tablets in adult patients with treatment-resistant depression through a randomized placebo-controlled phase 2 trial.

About the study The present phase 2 multicenter clinical trial was conducted across 20 psychiatric clinics in New Zealand, Australia, Singapore, and Taiwan. Following a 1-week open-label phase to exclude nonresponders, a 12-week double-blind phase assessed responders. The trial adhered to ethical standards and was registered .

The primary endpoint was the change in MADRS score from baseline to day 92, analyzed using analysis of covariance. Safety assessments included lab tests, Electrocardiograms , cognitive tests, and adverse event reports. The sample size aimed for significant MADRS score improvement with R-107 compared to placebo, involving 200 initial participants to ensure 150 randomized.

Related StoriesBy the end of the study , 100 participants had discontinued, 94 of whom were due to a lack of efficacy . Discontinuations were distributed as follows: placebo , 30 mg , 60 mg , 120 mg , and 180 mg . Completion rates ranged from 29.7% in the placebo group to 56.2% in the 180 mg group, with higher completion rates associated with higher R-107 doses. Treatment compliance was high, with 96.4% of participants reporting 80% or more compliance.

Source: Healthcare Press (healthcarepress.net)

Ketamine Antidepressant Efficacy Medicine Metabolites Placebo Research

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 19. in UK

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Netherlands chasing 107 to beat NepalNetherlands face Nepal at the Men's T20 World Cup in Grand Prairie, Texas - follow radio commentary & score updates.
Source: BBCSport - 🏆 111. / 51 Read more »

NBA Finals: Boston Celtics beat Dallas Mavericks 107-89 in game oneThe Boston Celtics take a 1-0 series lead against the Dallas Mavericks as they bid for a record 18th NBA Championship.
Source: BBCSport - 🏆 111. / 51 Read more »

Welsh Water boss claims ‘good progress’ despite 20% surge in pollution incidentsThe firm, which serves three million people in Wales, Herefordshire and parts of Deeside, recorded 107 pollution incidents in the last financial…
Source: Observer_Owl - 🏆 18. / 72 Read more »

Welsh Water boss claims ‘good progress’ despite 20% surge in pollution incidentsThe firm, which serves three million people in Wales, Herefordshire and parts of Deeside, recorded 107 pollution incidents in the last financial…
Source: Glasgow_Times - 🏆 76. / 59 Read more »

NBA play-offs: Dallas Mavericks go 3-0 up on Minnesota TimberwolvesThe Dallas Mavericks go 3-0 up in the Western Conference Finals after beating the Minnesota Timberwolves 116-107.
Source: BBCSport - 🏆 111. / 51 Read more »

CalMac contract to run west coast ferries extended by 12 monthsTHE contract for Government-owned ferry operator CalMac to run services on Scotland’s west coast has been extended by a year ...
Source: SunScotNational - 🏆 49. / 63 Read more »